Foundayo: What It Is, How It Works and What the Search Term Refers To

• GPhC registered UK pharmacy and weight loss clinic, registration number 9012878
• Plain English explanations of new weight loss medicines from a UK pharmacy team
• Online consultation with UK registered prescribers for weight management
• Independent prescriber review and clinical assessment before any supply

Foundayo is the brand name of orforglipron, a prescription-only, once-daily oral GLP-1 receptor agonist authorised in the UK for weight management and to improve glycaemic control in adults with insufficiently controlled type 2 diabetes. Unlike peptide GLP-1 medicines, orforglipron is a small-molecule, non-peptide GLP-1 receptor agonist designed for oral use.

For adults in the UK with obesity or type 2 diabetes who are looking into prescription weight management medicines, especially an oral alternative to injections, understanding exactly what Foundayo is and how it is used matters before treatment is considered. If you have seen the name in the news, on a pack or in a conversation and want to know what it refers to, this guide from the EveryDayMeds pharmacy team explains it from the ground up: what Foundayo is, how it works in the body, what it is licensed for, what the clinical trial evidence shows, what taking it involves, its side effects and safety considerations, and how it may be obtained through UK-registered prescribers and pharmacies.

What is Foundayo?

Foundayo is a medicine, not an ingredient, a supplement or a programme. The name is the brand under which orforglipron is sold, in the same way that most medicines have a generic name, which describes the active substance, and a brand name, which belongs to the product. The generic name is orforglipron. Both names refer to the same tablet.

Key things to know

• Foundayo contains orforglipron, a GLP-1 receptor agonist taken as a once daily tablet.
• The MHRA authorised it on 10 August 2026 for weight loss and weight maintenance in adults with a BMI of 30 or above, or 27 to 30 with at least one weight related condition, alongside a reduced calorie diet and increased physical activity, and to improve blood sugar control in adults with insufficiently controlled type 2 diabetes.
• Unlike peptide GLP-1 medicines, orforglipron is a small-molecule medicine that can be taken orally without food or water restrictions.
• In ATTAIN-1, 3,127 adults were randomised and followed for 72 weeks. At the highest dose, mean weight loss was 12.4% versus 0.9% with placebo using the efficacy estimand; using the treatment-regimen estimand, the figures were 11.2% and 2.1%, respectively.
• It is prescription only. A registered prescriber assesses eligibility and safety before supply, and dose steps are set by the prescriber.
• Side effects are mainly digestive and usually mild to moderate. The MHRA has said it will keep the medicine under close review.
• Treatment suitability depends on an individual clinical assessment, and your prescriber will determine the appropriate treatment.

Why does the search term have so many forms?

Because Foundayo is a new word. People who hear it on the radio, see it in a headline or read it on a prescription search for it in every way a spoken question can be typed: what is Foundayo, what Foundayo, tell me about Foundayo. The name has no meaning outside the medicine, so every one of those searches is asking the same thing, and this page answers it. If you have seen the name spelt differently, or heard it and are unsure of the spelling, the generic name orforglipron will find the same medicine.

How does Foundayo work?

Foundayo works by copying a hormone the body already makes. GLP-1, glucagon like peptide 1, is released by the gut after eating. It tells the brain that you have eaten, slows the emptying of the stomach so that fullness lasts longer, and prompts the pancreas to release insulin when blood sugar rises. Orforglipron activates the same receptors that GLP-1 activates, for longer and more steadily than the natural hormone, and the result is better appetite control to support weight loss, with less hunger, fewer cravings and smaller meals; results improve when Foundayo is used with nutritional adjustments alongside activity changes.

What does "small molecule" mean, and why does it matter?

A small molecule is a medicine built from a compact chemical structure rather than a chain of amino acids. The GLP-1 medicines that came before orforglipron are peptides, chains of amino acids like the natural hormone, which stomach acid and digestive enzymes break down.Many GLP-1-based medicines, including injectable semaglutide and tirzepatide, are peptide medicines and therefore require injection for systemic delivery. Oral semaglutide is also available, but it has specific fasting and water requirements.

Orforglipron is not a peptide. It passes through the stomach intact, is absorbed reliably with or without food, and can be taken at whatever time of day suits you.

Is Foundayo an injection?

No. Foundayo is a tablet taken once a day by mouth. The foundayo pill offers an oral alternative for people comparing it with weight loss injections. It does not need refrigeration, a needle, an injection technique or a weekly schedule. For people who cannot or do not want to inject, that is its main appeal, and it is the reason the MHRA's announcement of the licence drew attention across the UK.

What is Foundayo used for?

Foundayo is used for two things in the UK: weight management in adults who meet the licensed criteria, and blood sugar control in adults with type 2 diabetes that is insufficiently controlled.

Who is it not for?

Foundayo is not indicated for children or for use during pregnancy. Treatment should also be reviewed carefully in people with certain medical conditions, including previous pancreatitis, gallbladder disease or significant gastrointestinal problems. Your prescriber will assess your medical history, other medicines and individual risks before prescribing it.

What does the evidence show?

The evidence for Foundayo in weight management comes mainly from clinical trials in the ATTAIN programme, and ATTAIN-1 is the trial the UK licence rests on. It randomised 3,127 adults with obesity, or overweight with a weight related condition, and without diabetes, to one of three daily doses of orforglipron or placebo for 72 weeks, alongside advice on diet and physical activity.

The trial also reported improvements in waist circumference, blood pressure, cholesterol and blood sugar measures compared with placebo. Lower doses produced smaller average losses.

A separate trial programme, ACHIEVE, studied orforglipron in people with type 2 diabetes and supports the diabetes licence. Results vary between individuals, and an average includes people who lost much more and much less.

How does it compare with injectable medicines?

ATTAIN-1 was not a head-to-head trial, so its results cannot establish whether Foundayo produces more or less weight loss than a particular injectable medicine in comparable patients. Published trials of semaglutide and tirzepatide have reported different average weight-loss results, but those studies differed in design, participants, treatment duration and statistical analyses. Direct comparisons therefore need to be interpreted cautiously.

What does taking Foundayo involve?

Taking Foundayo involves a once daily tablet, a starting dose that the prescriber increases in steps, regular reviews, and a plan for eating and activity that runs alongside. The tablet can be taken at any time of day, with or without food, which makes it easier to fit into a routine than the tablet form of semaglutide.

1. Assessment. A registered prescriber confirms that you meet the licensed criteria and that the medicine is safe for you, asking about weight, health conditions, other medicines, pregnancy and previous treatment.
2. Starting. Treatment begins at a lower dose of 0.8 mg to let the digestive system adjust. The prescriber then guides each dose increase gradually up to the maximum dose of 17.2 mg, according to the licence and how you tolerate the medicine, and this is not something to speed up yourself.
3. The daily tablet. Take Foundayo once a day, at a time you can keep to. A missed dose is handled as the patient information leaflet directs, and never by doubling the next one.
4. Reviews. Side effects, weight and the diet and activity plan are reviewed at each dose step and at intervals afterwards.
5. Diet and activity. They form part of the overall weight-management plan. If treatment is stopped, maintaining dietary and activity changes may help support long-term weight management, although weight regain can occur after stopping weight-loss medicines.

What are the side effects of Foundayo?

The side effects of Foundayo are those of the GLP-1 class, mainly digestive, usually mild to moderate, and most frequent when the dose is increased. In ATTAIN-1 the main ones were nausea, vomiting, constipation and diarrhoea. Reduced appetite, reflux, belching, tiredness and dizziness are also reported across the class, and they often become less troublesome over time, although some people may continue to experience them.

What are the serious risks?

• Pancreatitis. Severe, persistent abdominal pain, sometimes spreading to the back, needs urgent medical attention. Foundayo should be discontinued if pancreatitis is suspected, and urgent medical assessment is required.
• Gallbladder problems. Rapid weight loss and GLP-1 medicines are both associated with gallstones. Pain under the right ribs, fever or yellowing of the skin or eyes needs a doctor.
• Dehydration and kidney problems from prolonged vomiting or diarrhoea. Keep fluids up and seek advice if you cannot keep them down.
• Low blood sugar in people also taking insulin or certain diabetes tablets, which may need adjusting.
• Effects on other medicines.Orforglipron can delay gastric emptying, which may affect the rate at which some oral medicines are absorbed. Tell your prescriber about all medicines you take so potential interactions can be assessed.
• Pregnancy. Not used.

The MHRA has said it will keep the safety and effectiveness of Foundayo under close review, and suspected side effects can be reported through the Yellow Card scheme. The patient information leaflet is published on the MHRA products website within the UK system for oversight of medicines and healthcare products.

What Foundayo is not

Understanding the name means understanding its limits, because a new medicine attracts claims that outrun the evidence.

• It is not a supplement. It is a licensed prescription medicine with a defined indication and a patient information leaflet.
• It is not over the counter. There is no legal supply without a prescription, and anything sold that way may be counterfeit.
• It is not a cure for obesity. It is a treatment for chronic weight management, and some people regain weight after treatment is stopped.
• It is not for everyone with weight to lose. The licence sets BMI and health criteria, and a prescriber applies them.
• It has not been shown to outperform injectable medicines. It has not been directly compared with injectable GLP-1 medicines in a head-to-head weight-management trial.
• It is not a reason to skip assessment. The medical history questions exist because the class has serious, if uncommon, risks.

How do you know a product sold as Foundayo is genuine?

A genuine product comes from a pharmacy on the GPhC register, after a consultation with a registered prescriber, and genuine supply may currently come via private prescriptions before any NHS access pathway is in place, with a private prescription and the UK patient information leaflet in the pack.

Tablets sold from social media accounts, marketplaces or overseas websites without a prescription may be counterfeit or unlicensed and may contain nothing, the wrong medicine or a harmful substance. The Medicines and Healthcare products Regulatory Agency, the MHRA, has repeatedly warned about counterfeit and unlicensed weight loss medicines sold online. If you have bought a product you doubt, do not take it, and report it through the Yellow Card scheme.

How can EveryDayMeds help?

If you have heard the name and want to know whether it could apply to you, an online consultation with UK registered prescribers assesses eligibility for GLP-1 based weight management against the licensed criteria and checks that treatment is safe alongside your health and your other medicines. An independent prescriber reviews your answers before anything is supplied and discusses the options, including whether Foundayo is available through our clinic at the time of your consultation, whether some patients ask if this new weight loss pill may be available privately before NHS commissioning decisions are made, and what the alternatives are if it is not, reflecting the practical challenges patients face. EveryDayMeds is a GPhC registered UK pharmacy and weight loss clinic, registration number 9012878.

Every medicine we supply is genuine and UK sourced, and our pharmacy team supports you through dose changes and side effects for as long as treatment continues. Medically supervised weight loss treatment is available to adults living with obesity, subject to an individual clinical assessment, with treatment aimed to help eligible adults reduce excess body weight through chronic weight management.

Medical Disclaimer

This article is for general information only and does not replace advice from a doctor, pharmacist or other qualified healthcare professional. It does not recommend any specific medicine or dose. Foundayo is a prescription only medicine that should only be used under the supervision of an appropriately qualified prescriber, within its UK licence. Always read the patient information leaflet. If you have severe abdominal pain, cannot keep fluids down, or notice yellowing of the skin or eyes, seek urgent medical attention.